{
    "clinical_study": {
        "@rank": "25269", 
        "brief_summary": {
            "textblock": "To evaluate the pharmacokinetics of intravenous ganciclovir in children (ages 3 months - 12\n      years). To determine the safety and tolerance of a 2 to 3 week induction course of\n      ganciclovir IV in immunocompromised children receiving treatment for life- or\n      sight-threatening cytomegalovirus infections."
        }, 
        "brief_title": "An Open Label Evaluation of the Safety and Pharmacokinetics of Ganciclovir in Children", 
        "condition": [
            "Cytomegalovirus Retinitis", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Retinitis", 
                "Cytomegalovirus Retinitis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Topical acyclovir.\n\n          -  Consult with the Syntex study monitor for the following:\n\n          -  Cytokines.\n\n          -  Soluble CD4.\n\n          -  Trichosanthin (Compound Q).\n\n          -  Imipenem-cilastatin.\n\n          -  Other investigational drugs.\n\n        Patients must have the following:\n\n          -  Congenital or acquired immune deficiency.\n\n          -  Eligibility to receive ganciclovir for the treatment of life- or sight-threatening\n             Cytomegalovirus (CMV) disease.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following conditions or symptoms are excluded:\n\n          -  Mild to moderate Cytomegalovirus infection that does not satisfy the clinical\n             severity criteria.\n\n          -  Congenital or neonatal CMV infections without documented congenital or acquired\n             immunodeficiency.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Other myelosuppressive drugs.\n\n          -  Antimetabolites.\n\n          -  Alkylating agents.\n\n          -  Nucleoside analogs (topical acyclovir is allowed).\n\n          -  Interferons.\n\n          -  Foscarnet.\n\n          -  Consult with the Syntex study monitor for the following:\n\n          -  Cytokines.\n\n          -  Soluble CD4.\n\n          -  Trichosanthin (Compound Q).\n\n          -  Imipenem-cilastatin.\n\n          -  Other investigational drugs.\n\n        Patients with the following are excluded:\n\n          -  Mild to moderate Cytomegalovirus (CMV) infection that does not meet the clinical\n             severity criteria.\n\n          -  Absolute neutrophil count (ANC) < 500 cells/mm3 or a platelet count < 25000\n             platelets/mm3.  Note:\n\n          -  Exceptions may be made for patients with pre-existing neutropenia or thrombocytopenia\n             and immediately life-threatening disease, if the investigator believes that a delay\n             in starting ganciclovir therapy is not advisable. In such patients, the investigator\n             should advise the parents or guardians of the risk of further bone marrow suppression\n             and the increased risk of infection or bleeding.\n\n          -  Receiving excluded medications that it is not possible to discontinue.\n\n          -  Congenital or neonatal CMV infections without documented congenital or acquired\n             immunodeficiency.\n\n          -  Demonstrated hypersensitivity to acyclovir or ganciclovir."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "12 Years", 
            "minimum_age": "3 Months"
        }, 
        "enrollment": "20", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002015", 
            "org_study_id": "029G", 
            "secondary_id": "ICM 1788"
        }, 
        "intervention": {
            "intervention_name": "Ganciclovir", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Ganciclovir"
        }, 
        "keyword": [
            "Retinitis", 
            "Ganciclovir", 
            "Cytomegalovirus Infections", 
            "Acquired Immunodeficiency Syndrome", 
            "Immunocompromised Host"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35294"
                    }, 
                    "name": "Univ of Alabama at Birmingham"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90095"
                    }, 
                    "name": "Ctr for the Health Sciences / UCLA Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90033"
                    }, 
                    "name": "Los Angeles County - USC Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90027"
                    }, 
                    "name": "Children's Hosp of Los Angeles"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60637"
                    }, 
                    "name": "Univ of Chicago / Wylers"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Omaha", 
                        "country": "United States", 
                        "state": "Nebraska", 
                        "zip": "681983280"
                    }, 
                    "name": "Univ of Nebraska Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14642"
                    }, 
                    "name": "Univ of Rochester Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "Baylor College of Medicine / Texas Children's Hosp"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "An Open Label Evaluation of the Safety and Pharmacokinetics of Ganciclovir in Children", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002015"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Roche Global Development", 
                "agency_class": "Other"
            }
        }, 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 1996"
    }, 
    "geocoordinates": {
        "Baylor College of Medicine / Texas Children's Hosp": "29.76 -95.369", 
        "Children's Hosp of Los Angeles": "34.052 -118.244", 
        "Ctr for the Health Sciences / UCLA Med Ctr": "34.052 -118.244", 
        "Los Angeles County - USC Med Ctr": "34.052 -118.244", 
        "Univ of Alabama at Birmingham": "33.521 -86.802", 
        "Univ of Chicago / Wylers": "41.878 -87.63", 
        "Univ of Nebraska Med Ctr": "41.252 -95.998", 
        "Univ of Rochester Med Ctr": "43.161 -77.611"
    }
}